Quarterly results · SUPHA
SUPHA PHARMACHEM LIMITED reported revenue of ₹111 cr and net profit of ₹8.62 cr in Q2 FY26 (quarter ended 30 Sept 2025). Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
| Quarter | Q2 FY26 |
|---|---|
| Quarter ended | 30 Sept 2025 |
| Revenue | ₹111 cr |
| Revenue YoY | — |
| Operating profit | ₹7.37 cr |
| Operating margin | 6.6% |
| Net profit | ₹8.62 cr |
| Net profit YoY | — |
| Net profit QoQ | +85.5% |
| Net margin | 7.8% |
| Basic EPS | ₹0.10 |
| TTM revenue | ₹527 cr |
| TTM net profit | ₹11.99 cr |
| TTM net margin | 2.3% |
SUPHA PHARMACHEM LIMITED (SUPHA) has reported its Q2 FY26 results for the quarter ended 2025-09-30. The company posted revenue of ₹111 cr and a net profit of ₹8.62 cr, translating into earnings per share of ₹0.10.
Operating profit for the quarter stood at ₹7.37 cr, an operating margin of 6.6%.
Revenue
₹111 cr
— YoY
Net profit
₹8.62 cr
— YoY
Operating profit
₹7.37 cr
— YoY
EPS
₹0.10
— YoY
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q2 FY262025-09-30 | ₹111 cr | ₹7.37 cr | ₹8.62 cr | 6.6% | 7.8% | ₹0.10 | — | +85.5% |
| Q1 FY262025-06-30 | ₹113 cr | ₹1.87 cr | ₹4.65 cr | 1.7% | 4.1% | ₹0.05 | — | +327.2% |
| Q4 FY252025-03-31 | ₹264 cr | ₹1.89 cr | -₹2.05 cr | 0.7% | -0.8% | — | — | -367.6% |
| Q3 FY252024-12-31 | ₹38.15 cr | -₹5.49 cr | ₹0.76 cr | -14.4% | 2.0% | ₹0.01 | — | — |
| TTM (last 4 quarters) | ₹527 cr | ₹5.65 cr | ₹11.99 cr | 1.1% | 2.3% | — | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q2 FY262025-09-30 | Q1 FY262025-06-30 | Q4 FY252025-03-31 | Q3 FY252024-12-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹111 cr | ₹113 cr | ₹264 cr | ₹38.15 cr |
| Total expenses | ₹104 cr | ₹111 cr | ₹262 cr | ₹43.64 cr |
| Gross profit | ₹10.59 cr | ₹5.54 cr | ₹1.65 cr | -₹2.28 cr |
| Operating profit (EBIT) | ₹7.37 cr | ₹1.87 cr | ₹1.89 cr | -₹5.49 cr |
| Operating margin | 6.6% | 1.7% | 0.7% | -14.4% |
| Interest cost | ₹0.19 cr | — | ₹3.92 cr | ₹0.88 cr |
| Profit before tax | ₹10.44 cr | ₹5.71 cr | -₹1.4 cr | ₹1.06 cr |
| Tax expense | ₹1.81 cr | ₹1.06 cr | ₹0.65 cr | ₹0.29 cr |
| Effective tax rate | 17.4% | 18.6% | -46.1% | 27.8% |
| Net profit (PAT) | ₹8.62 cr | ₹4.65 cr | -₹2.05 cr | ₹0.76 cr |
| Net profit margin | 7.8% | 4.1% | -0.8% | 2.0% |
| Basic EPS | ₹0.10 | ₹0.05 | — | ₹0.01 |
| Diluted EPS | ₹0.10 | ₹0.05 | — | ₹0.01 |
| Growth | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 |
|---|---|---|---|---|
| Revenue YoY | — | — | — | — |
| Revenue QoQ | -2.0% | -57.1% | +592.8% | — |
| Operating profit YoY | — | — | — | — |
| Operating profit QoQ | +294.0% | -1.2% | +134.5% | — |
| Net profit YoY | — | — | — | — |
| Net profit QoQ | +85.5% | +327.2% | -367.6% | — |
| EPS YoY | — | — | — | — |
| EPS QoQ | +100.0% | — | — | — |
Full-year performance for SUPHA PHARMACHEM LIMITED, useful for reading each quarter in context.
| Particulars | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 | FY222022-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹405 cr | ₹4,042 cr | ₹510 cr | ₹505 cr |
| Total expenses | ₹404 cr | ₹4,008 cr | ₹501 cr | ₹503 cr |
| Gross profit | ₹7.12 cr | ₹40.33 cr | ₹15.98 cr | ₹6.31 cr |
| Operating profit (EBIT) | ₹1.23 cr | ₹34.15 cr | ₹8.57 cr | ₹1.74 cr |
| Operating margin | 0.3% | 0.8% | 1.7% | 0.3% |
| Interest cost | ₹7.62 cr | ₹4.02 cr | ₹0.07 cr | ₹0.18 cr |
| Profit before tax | ₹4.38 cr | ₹50.45 cr | ₹7.4 cr | ₹1.53 cr |
| Tax expense | ₹2.25 cr | ₹17.72 cr | ₹1.97 cr | ₹0.45 cr |
| Effective tax rate | 51.4% | 35.1% | 26.6% | 29.3% |
| Net profit (PAT) | ₹2.13 cr | ₹32.73 cr | ₹5.43 cr | ₹1.08 cr |
| Net profit margin | 0.5% | 0.8% | 1.1% | 0.2% |
| Basic EPS | ₹0.03 | ₹0.57 | ₹0.09 | ₹0.02 |
| Diluted EPS | ₹0.03 | ₹0.57 | ₹0.09 | ₹0.02 |
Topline for Q2 FY26 came in at ₹111 cr, and ₹113 cr in the preceding Q1 FY26 quarter.
On a sequential basis revenue declined -2.0%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹104 cr, or 93.4% of revenue.
Net profit of ₹8.62 cr works out to a net margin of 7.8%.
Below the operating line, SUPHA PHARMACHEM LIMITED reported profit before tax of ₹10.44 cr, a tax charge of ₹1.81 cr (effective rate 17.4%), interest cost of ₹0.19 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹4.65 cr in Q1 FY26 to ₹8.62 cr in Q2 FY26, a change of +85.5%.
Across the trailing four quarters SUPHA PHARMACHEM LIMITED has generated revenue of ₹527 cr and net profit of ₹11.99 cr, a trailing net margin of 2.3%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY25 revenue was ₹405 cr with net profit of ₹2.13 cr and EPS of ₹0.03, versus the prior year where revenue declined -90.0% and profit declined -93.5%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
SUPHA PHARMACHEM LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
No results report published for SUPHA yet — our desk covers each quarter within minutes of the filing.
In Q2 FY26 (quarter ended 30 Sept 2025), SUPHA PHARMACHEM LIMITED reported revenue of ₹111 cr and net profit of ₹8.62 cr. EPS stood at ₹0.10.
SUPHA PHARMACHEM LIMITED posted a net profit margin of 7.8% and an operating margin of 6.6% in Q2 FY26. On a trailing twelve-month basis, revenue is ₹527 cr and net profit ₹11.99 cr.
SUPHA PHARMACHEM LIMITED net profit changed +85.5% quarter on quarter, from ₹4.65 cr in Q1 FY26 to ₹8.62 cr in Q2 FY26.
SUPHA PHARMACHEM LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Results coverage for SUPHA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the SUPHA stock page.
For FY25, SUPHA PHARMACHEM LIMITED reported full-year revenue of ₹405 cr and net profit of ₹2.13 cr, with EPS of ₹0.03.
Past results dates for SUPHA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
